PF03716556
-
PF03716556
structure -
-
CAS No:
928774-43-0
-
Formula:
C22H26N4O3
-
Chemical Name:
PF03716556
-
Synonyms:
PF03716556;PF 3716556;8-[[(4R)-3,4-Dihydro-5-Methyl-2H-1-benzopyran-4-yl]aMino]-N-(2-hydroxyethyl)-N,2-diMethyliMidazo[1,2-a]pyridine-6-carboxaMide;N-(2-Hydroxyethyl)-N,2-diMethyl-8-{[(4R)-5-Methyl-3,4-dihydro-2H-chroMen-4-yl]aMino}iMidazo[1,2-a]pyridine-6-carboxa;PF3716556/PF-3716556/PF-03716556;(R)-N-(2-hydroxyethyl)-N,2-dimethyl-8-(5-methyl-3,4-dihydro-2H-chromen-4-ylamino)H-imidazo[1,2-a]pyridine-6-carboxamide;8-[[(4R)-3,4-Dihydro-5-methyl-2H-1-benzopyran-4-yl]amino]-N-(2-hydroxyethyl)-N,2-dimethylimidazo[1,2-a]pyridine-6-carboxamide PF 03716556;[N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide]
- Categories:
-
CAS No:
Description
PF 03716556 is a potent, and selective acid pump (H+,K+ ATPase) antagonist, with pIC50 value of 6.009.IC50 value:6.009 (pIC50)Target: H+,K+ ATPasePF-03716556 inhibited the activity of H+, K+-ATPase with pIC50 of 6.026 ± 0.112, 6.038 ± 0.039 and 6.009 ± 0.209 at pH 6.4 for porcine, canine and human ion-leaky membrane vesicles, respectively. PF-03716556 (PF03716556) is useful for treatment of gastroesophageal reflux disease.
Drug Information
N-(2-hydroxyethyl)-N,2-dimethyl-8-((5-methyl-3,4-dihydro-2H-chromen-4-yl)amino)imidazo(1,2-a)pyridine-6-carboxamide
PF03716556 Use and Manufacturing
A novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Computed Properties
Molecular Weight:394.5
XLogP3:2.9
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:5
Exact Mass:394.20049070
Monoisotopic Mass:394.20049070
Topological Polar Surface Area:79.1
Heavy Atom Count:29
Complexity:576
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of PF03716556
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Latest News on PF03716556
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4